Jan Stritzke

Jan Stritzke

Auto-generated profile, based on publicly available information

Jan Stritzke

Medical Clinic II, University of Lübeck Medical School, Lübeck, Germany

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 July 2009 in JAMA
Verified
Journal Article
Open access
PDF file
RVRamachandran S. Vasan
Ramachandran S. Vasan
NGNicole L. Glazer
Nicole L. Glazer
JFJanine F. Felix
Janine F. Felix
WLWolfgang Lieb
Wolfgang Lieb
PWPhilipp S. Wild
Philipp S. Wild
SBStefan Blankenberg
Stefan Blankenberg
Alterations in cardiac structure and function adversely affect the prognosis of individuals in the general population. In community-based cohorts, the presence of left ventricular (LV) hypertrophy and increased LV mass predict the development of coronary heart disease,1,2 congestive heart failure (CHF),2 stroke,2,3 cardiovascular disease (CVD), and all-cause mortality.2,4 Likewise, increased LV wall thickness predicts CVD events,5 LV dilation predicts CHF,6 and asymptomatic LV systolic dysfunction predicts CHF and death.7 Left atrial size is related to incidence of atrial fibrillation,5 stroke, and death.8 Aortic root size is associated with risk of CHF, stroke, and mortality.8,9 Thus, traits obtained from echocardiography serve not only as measures of cardiac structure and function but also as intermediate phenotypes for clinical CVD outcomes.

1 November 2009 in JACC
Verified
Journal Article
Closed access
JSJan Stritzke
Jan Stritzke
MMMarcello Ricardo Paulista Markus
Marcello Ricardo Paulista Markus
SDStefanie Duderstadt
Stefanie Duderstadt
WLWolfgang Lieb
Wolfgang Lieb
ALAndreas Luchner
Andreas Luchner
HSHeribert Schunkert
Heribert Schunkert

11 November 2005 in Journal of Molecular Medicine
Verified
Journal Article
Closed access
PDF file
WLWolfgang Lieb
Wolfgang Lieb
JGJochen Graf
Jochen Graf
AGAnika Götz
Anika Götz
IKInke R. König
Inke R. König
BMBjörn Mayer
Björn Mayer
Jeanette ErdmannJeanette Erdmann
Jeanette Erdmann

1 August 2013 in European Journal of Heart Failure
Verified
Journal Article
Open access
PDF file
ALAndreas Luchner
Andreas Luchner
GBGundula Behrens
Gundula Behrens
JSJan Stritzke
Jan Stritzke
MMMarcello Ricardo Paulista Markus
Marcello Ricardo Paulista Markus
KSKlaus Stark
Klaus Stark
IHIris M. Heid
Iris M. Heid
Aims The natriuretic peptides BNP and NT‐proBNP are potent cardiac markers, but knowledge of long‐term changes is sparse. We thus quantified determinants of change in BNP and NT‐proBNP in a study of south German residents (KORA). Methods and results A total of 1005 men and women (age 25–74 years, mean 48 years) underwent physical examination and echocardiography at baseline and at follow‐up after 10 years. The current analysis comprised 877 subjects with dual measurements of BNP and NT‐proBNP. Both markers increased in both sexes (P < 0.001) during the 10‐year follow‐up, and higher levels in women persisted across time (P for sex difference <0.001). Among baseline covariates, predictors for 10‐year change of NT‐proBNP, BNP, or both were age, sex, diabetes status, and heart rate (multivariable regression analysis, each P < 0.05). However, changes of covariates over the 10‐year follow‐up were much stronger determinants. Specifically, incident myocardial infarction, new beta‐blocker medication, and increased cardiac parameters (left atrial diameter, LV end‐diastolic diameter, and LV mass index) were associated with increasing BNP, NT‐proBNP, or both, whereas increased heart rate, haematocrit, and body mass index (BMI) were associated with decreasing BNP and NT‐proBNP (all P < 0.05). Conclusion Next to ageing and sex, a variety of changes in covariates reflecting the sequelae of cardiac remodelling as well as myocardial infarction and diabetes influence long‐term changes of BNP and NT‐proBNP. Of note, diabetes and increased BMI exert opposite effects. For interpretation of individual marker concentrations, a host of covariates needs to be considered, especially in subjects without prevalent or incident cardiac disease.

25 July 2012 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MHMaria F Hughes
Maria F Hughes
OSOlli Saarela
Olli Saarela
JSJan Stritzke
Jan Stritzke
FKFrank Kee
Frank Kee
KSKaisa Silander
Kaisa Silander
HSHeribert Schunkert
Heribert Schunkert
More accurate coronary heart disease (CHD) prediction, specifically in middle-aged men, is needed to reduce the burden of disease more effectively. We hypothesised that a multilocus genetic risk score could refine CHD prediction beyond classic risk scores and obtain more precise risk estimates using a prospective cohort design. Using data from nine prospective European cohorts, including 26,221 men, we selected in a case-cohort setting 4,818 healthy men at baseline, and used Cox proportional hazards models to examine associations between CHD and risk scores based on genetic variants representing 13 genomic regions. Over follow-up (range: 5–18 years), 1,736 incident CHD events occurred. Genetic risk scores were validated in men with at least 10 years of follow-up (632 cases, 1361 non-cases). Genetic risk score 1 (GRS1) combined 11 SNPs and two haplotypes, with effect estimates from previous genome-wide association studies. GRS2 combined 11 SNPs plus 4 SNPs from the haplotypes with coefficients estimated from these prospective cohorts using 10-fold cross-validation. Scores were added to a model adjusted for classic risk factors comprising the Framingham risk score and 10-year risks were derived. Both scores improved net reclassification (NRI) over the Framingham score (7.5%, p = 0.017 for GRS1, 6.5%, p = 0.044 for GRS2) but GRS2 also improved discrimination (c-index improvement 1.11%, p = 0.048). Subgroup analysis on men aged 50–59 (436 cases, 603 non-cases) improved net reclassification for GRS1 (13.8%) and GRS2 (12.5%). Net reclassification improvement remained significant for both scores when family history of CHD was added to the baseline model for this male subgroup improving prediction of early onset CHD events. Genetic risk scores add precision to risk estimates for CHD and improve prediction beyond classic risk factors, particularly for middle aged men.

31 July 2006 in Nephrology Dialysis Transplantation
Verified
Journal Article
Closed access
PDF file
WLWolfgang Lieb
Wolfgang Lieb
BMBjoern Mayer
Bjoern Mayer
JSJan Stritzke
Jan Stritzke
ADAngela Doering
Angela Doering
HHHans-Werner Hense
Hans-Werner Hense
HSHeribert Schunkert
Heribert Schunkert
Background. Even mild renal dysfunction is a predictor of cardiovascular morbidity. We investigated whether sub-threshold microalbuminuria or mildly decreased estimated glomerular filtration rate (eGFR) are related to left ventricular hypertrophy (LVH) in the general population.